Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Idec Makes A Case For Neurology

This article was originally published in The Pink Sheet Daily

Executive Summary

Management laid out Biogen's neurology pipeline to investors Nov. 30, but most of the drugs are in early development.

You may also be interested in...

ALS TDI Advances Two Drugs Toward The Clinic

The non-profit research organization, focused on the development of drugs for the treatment of ALS, is making clinical progress on two drugs, one of which is Novartis’ Gilenya.

Biogen Idec Lays Off 13 Percent of Staff, Retrenches Around Multiple Sclerosis

Saying his new company is spread "a mile wide and an inch deep," Biogen Idec Inc.'s CEO George Scangos, PhD, affirmed Nov. 3 that the big biotech firm will drastically pare its pipeline, cut 13% of staff, and refocus its efforts around its historic strength – its multiple sclerosis franchise.

UCB Provides Synosia With Its First Out-Licensing Deal And Leads Its $30M Series C Funding

UCB gains rights to Synosia's potential Parkinson's disease therapies in deal that could be worth $725 million in milestones

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts